WO2024213932 - DRIVING AXON REGENERATION BY NOVEL ENPP1 INHIBITORS

National phase entry is expected:
Publication Number WO/2024/213932
Publication Date 17.10.2024
International Application No. PCT/IB2024/000162
International Filing Date 09.04.2024
Title **
[English] DRIVING AXON REGENERATION BY NOVEL ENPP1 INHIBITORS
[French] COMMANDE DE RÉGÉNÉRATION D'AXONES PAR DE NOUVEAUX INHIBITEURS D'ENPP1
Applicants **
THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventors
LIU, Kai
HUANG, Yong
CHAN, Leung, Ting
YANG, Chao
Priority Data
63/495,541   11.04.2023   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting1605
EPO Filing, Examination, Granting11576
Japan Filing, Examination, Granting2031
South Korea Filing, Examination, Granting1871
USA Filing, Examination, Granting5340
MasterCard Visa
Total: 22,423

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] A neurite growth stimulator is a small molecule ENPP1 inhibitor. The small molecule ENPP1 inhibitor allows treatment of a central nervous system (CNS) injury with promotion of axon regeneration. The ENPP1 inhibitor in a vehicle can be administered to a neurological injury to promote the regeneration of axons.[French] Un stimulateur de croissance de neurites est un inhibiteur d'ENPP1 à petites molécules. L'inhibiteur d'ENPP1 à petites molécules permet le traitement d'une lésion du système nerveux central (SNC) avec la promotion de la régénération d'axones. L'inhibiteur d'ENPP1 dans un véhicule peut être administré à une lésion neurologique pour favoriser la régénération d'axones.